key: cord-0851831-4wbkis5w
authors: Crothers, Kristina; DeFaccio, Rian; Tate, Janet; Alba, Patrick R.; Goetz, Matthew Bidwell; Jones, Barbara; King, Joseph T.; Marconi, Vincent; Ohl, Michael E.; Rentsch, Christopher T.; Rodriguez-Barradas, Maria C.; Shahrir, Shahida; Justice, Amy C.; Akgün, Kathleen M.
title: Dexamethasone in hospitalised coronavirus-19 patients not on intensive respiratory support
date: 2021-11-25
journal: Eur Respir J
DOI: 10.1183/13993003.02532-2021
sha: 693332bd829bab4e8e0b413d962fe089669e96d2
doc_id: 851831
cord_uid: 4wbkis5w

INTRODUCTION: Dexamethasone decreases mortality in coronavirus disease 2019 (COVID-19) patients on intensive respiratory support (IRS) but is of uncertain benefit if less severely ill. We determined whether early (within 48 h) dexamethasone was associated with mortality in patients hospitalised with COVID-19 not on IRS. METHODS: We included patients admitted to Veterans Affairs hospitals between June 7, 2020-May 31, 2021 within 14-days after SARS-CoV-2 positive test. Exclusions included recent prior corticosteroids and IRS within 48 h. We used inverse probability of treatment weights (IPTW) to balance exposed and unexposed groups, and Cox proportional hazards models to determine 90-day all-cause mortality. RESULTS: Of 19 973 total patients (95% men, median age 71, 27% black), 15 404 (77%) were without IRS within 48 h. Of these, 3514/9450 (34%) patients on no oxygen received dexamethasone and 1042 (11%) died; 4472/5954 (75%) patients on low-flow nasal cannula (NC) received dexamethasone and 857 (14%) died. In IPTW stratified models, patients on no oxygen who received dexamethasone experienced 76% increased risk for 90-day mortality (hazard ratio [HR] 1.76, 95% confidence interval [CI] 1.47 to 2.12); there was no association with mortality among patients on NC (HR 1.08, 95% CI 0.86 to 1.36). CONCLUSION: In patients hospitalised with COVID-19, early initiation of dexamethasone was common and was associated with no mortality benefit among those on no oxygen or NC in the first 48 h; instead, we found evidence of potential harm. These real-world findings do not support the use of early dexamethasone in hospitalised COVID-19 patients without IRS.

Corticosteroids have emerged as an effective therapy for critically ill patients with COVID-19.

The large United Kingdom RECOVERY trial RCT of corticosteroids in COVID-19 patients demonstrated an overall 2.8% absolute decrease in mortality for patients treated with dexamethasone compared to usual care. [1] When stratified by respiratory support at randomization, dexamethasone was associated with greater benefit amongst those on invasive mechanical ventilation (IMV) versus supplemental oxygen (inclusive of non-invasive mechanical ventilation [NIV] ); dexamethasone was not significantly associated with mortality in those not on oxygen. Dissemination of these and other results led to rapid uptake in use of corticosteroids for COVID-19 patients, particularly those receiving more intensive respiratory support (IRS) such as high-flow nasal cannula (HFNC), NIV and IMV. [2] [3] [4] [5] [6] However, whether corticosteroids are beneficial in all patients with COVID-19 remains uncertain. The association between corticosteroids and outcomes among a wider group of patients with COVID-19including a larger proportion without IRS than in the RECOVERY trialhas been mixed. [7] [8] [9] [10] [11] Variability in the effect of corticosteroids may be due to numerous factors. A recent Cochrane review concluded that systemic corticosteroids "probably reduce allcause mortality slightly" but that there is an "urgent need for good-quality evidence for specific subgroups of disease severity, for which we propose level of respiratory support at randomization." [12] We determined the association between corticosteroids and 90-day all-cause mortality using real-these reasons, as well as the greater clinical equipoise, we restricted our analysis to patients without IRS (specifically, no oxygen or only low-flow NC support).

In those without IRS, we compared mortality by exposure to dexamethasone overall and stratified by NC. To account for confounding by indication, we generated propensity scores for the probability of receiving dexamethasone in the first 48 hours using logistic regression. Models included covariates associated with dexamethasone exposure and mortality: comorbidities, laboratory results, vital signs, site utilization patterns, co-medications and the time phases (Table   2 and Supplement Table 1 ). We constructed inverse probability of treatment weights (IPTW) from propensity scores for each patient to create pseudo-populations with balanced distributions of covariates. [19] In our primary analysis, we used average treatment effect (ATE) weights, reflecting the overall population from which the sample was taken. We used stabilized weights and trimmed from analysis the ten patients with the most extreme high and low weights.

[20] We calculated standardized mean differences (SMD) between treatment groups and considered 0.2 or less as balanced. Using days since index date as the time scale, we compared differences in survival using weighted Kaplan-Meier (KM) plots [21] and estimated ATE using Cox proportional hazards models to generate hazard ratio (HR) and confidence limits using a robust variance estimator. We included the VACO Index in outcome models to further account for residual confounding. [16] Subgroup and sensitivity analyses: In subgroup analyses, we excluded patients admitted to the ICU within the first 48 hours, and restricted to those age 70 and older. In sensitivity analyses, we limited the window between a positive SARS-CoV-2 test to within 24 or 48 hours of index date;

In addition, we considered exposure to any systemic corticosteroids within the first 48 hours. We also evaluated the average treatment effect among the treated (ATT) population that received dexamethasone in weighted Cox proportional hazards models, and constructed unweighted, but multivariable adjusted models for all primary and subgroup analyses (Supplement Tables 2 and   3 ). Table 4 ).

Patients hospitalized during the seven phases (n=19,973) were mostly male (95%). Median age was 71 years (interquartile range [IQR] 62-77); 55% were non-Hispanic white, 27% non-Hispanic black, and 9% Hispanic (Table 1) . Most patients (83%) were admitted within one day after positive SARS-CoV-2 test. More than half overall (60%) received corticosteroids within 48 hours, of whom 95% received dexamethasone. Concurrent remdesivir and prophylactic anticoagulants initiated within 48 hours of admission were more common in those who received dexamethasone than in those who did not (remdesivir 43% vs. 13%; anticoagulants 46% vs.

10%, respectively).

When stratified by highest level of respiratory support in the first 48 hours of admission, 77% of patients were on either no oxygen (47%) or NC only (30%) ( Table 1) . Dexamethasone was administered to 34% without oxygen, 75% on NC, 69% on other supplemental oxygen/NIV, 91% on HFNC, and 90% on IMV. Use of dexamethasone generally increased over time ( Figure   2 ). Overall, unadjusted 90-day mortality was 17% and varied by respiratory support (Figure 2 ).

Amongst patients without IRS, the median duration of inpatient dexamethasone administration was 5 days (IQR [3] [4] [5] [6] [7] [8] in patients without oxygen, and 6 days (IQR [4] [5] [6] [7] [8] [9] in patients on NC. These were similar to hospital length of stay (Table 1 ). Only 341 (3.6%) and 115 (1.9%) patients, respectively, received only one day of inpatient dexamethasone.

After propensity score weighting, our samples (pseudopopulations) were well-balanced (Table 2 and Supplement Table 1 ). Among patients without oxygen, weighted KM curves ( Figure 3 ) show that those who received dexamethasone had higher mortality over 90-days than those who did not, with differences beginning to appear 10-days after index date. In ATE estimates (Table 3) , patients without oxygen who received dexamethasone had an 76% increased hazard of 90-day mortality (HR 1.76, 95% CI 1.47 to 2.12).

In patients on NC, 90-day mortality was similar in those who did and did not receive dexamethasone, as shown in weighted KM curves ( Figure 3) . ATE estimates demonstrated a non-significant 8% increased mortality risk (HR 1.08, 95% CI 0.86 to 1.37) in patients on NC who received dexamethasone. When combining patients on no oxygen or NC, dexamethasone was associated with approximately 60% or more increased mortality risk.

Results were similar in subgroup analyses excluding patients admitted to ICU within the first 48 hours and limiting the sample to patients age 70 and older (Table 3 ). Findings were also consistent considering SARS-CoV-2 testing within 24 or 48 hours of index date, exposure to all corticosteroids, and when using ATT or multivariable Cox models (Supplement Tables 2 and 3 ).

Among patients on NC, HRs were similar using ATT estimates, but dexamethasone was associated with a statistically significant increase in mortality in multivariable Cox models (HR 1.31, 95% CI 1.08-1.60, Supplemental Table 3 ).

In this US national cohort of hospitalized patients with COVID-19, dexamethasone use was common and increased over time. Among patients on IRS, 90% received dexamethasone within 48 hours of admission. Focusing on patients without IRS, where there is less evidence supporting corticosteroid use, we found that among patients without oxygen in the first 48 hours, dexamethasone was administered in 34% and was associated with 76% increased 90-day mortality. Among those on NC in the first 48 hours, dexamethasone was administered in 75%

and was associated with no mortality benefit. This real-world evidence does not support the use of dexamethasone in hospitalized COVID-19 patients without IRS in the first 48 hours.

While we cannot rule out residual confounding, our findings were robust employing several different approaches and in subgroup and sensitivity analyses, including limiting the time window for SARS-CoV-2 test result, exposure to any systemic corticosteroid, restricted to patients over age 70 and excluding those who were admitted to the ICU within 48 hours. Results were consistent using ATE, reflecting the overall population from which the sample was taken, and using ATT, reflecting the population who received dexamethasone. They were also consistent controlling for potential confounders such as demographics, phase of the pandemic, site prescribing patterns, comorbidities, vital signs, laboratory values and co-administration of medications including remdesivir. [16] Importantly, patients without IRS in the initial 48 hours represent the majority (77%) of COVID-19 admissions in the cohort; thus, our findings have important clinical implications on the potential unintended consequences of widespread dexamethasone adoption for COVID-19 amongst patients who are without IRS. We found that uptake of dexamethasone for COVID-19 patients hospitalized in the VA was rapid after release of the RECOVERY trial results in early June 2020. By mid-July 2020 most facilities had increased the proportion of patients administered dexamethasone to 90% of patients on HFNC or IMV within 48 hours of admission, exceeding national estimates from other health systems. [6] However, sites also increased use of dexamethasone for patients with less severe COVID-19, including those not on oxygen or only on NC (Figure 2 ), suggesting indication creep.

Our results provide real world evidence of practice patterns and extend findings from RECOVERY. [1] We provide clinically actionable evidence demonstrating significantly and substantially increased mortality in hospitalized COVID-19 patients not on oxygen who received early dexamethasone. Moreover, our results inform an area of significant clinical uncertainty, namely the use of dexamethasone in COVID-19 patients with less severe respiratory failure.

Clinical guidelines issued by the US National Institutes of Health provide a moderate recommendation for corticosteroids in hospitalized COVID-19 patients "on supplemental oxygen." [22] While dexamethasone was associated with improved outcomes in patients on oxygen support in RECOVERY, this category included all forms of oxygen, except for IMV, but inclusive of NIV. We further stratified patients by level of oxygen support during the initial 48 hours of hospitalization, addressing a significant knowledge gap. [12] We found a lack of benefit associated with dexamethasone in patients on only low-flow NC within 48 hours of admission, suggesting that use of corticosteroids in this population should be re-considered and requires further prospective study.

Even before COVID-19, the impact of corticosteroids has been inconsistent in other causes of pneumonia including influenza, community-acquired pneumonia (CAP), and the original severe acute respiratory syndrome (SARS). [8, [23] [24] [25] [26] . The impact of corticosteroids likely depends on multiple factors, including patient age and other characteristics, heterogeneity in host response to infection, etiology of pneumonia, time since onset of infection and presence and severity of acute respiratory distress syndrome (ARDS). [8, 10, [27] [28] [29] [30] [31] While corticosteroids may decrease host inflammatory response, potentially modulating lung injury, they may also have harmful side effects or unintended consequences on adaptive immune responses that may be important to resolution of infection and increase risk of secondary infection.

There remain unanswered questions regarding the use of dexamethasone for patients hospitalized with COVID-19, particularly those without IRS. For some patients, initiation within 48 hours of hospitalization may be too early and could impair viral clearance.

[32] While most patients in our cohort had positive SARS-CoV-2 testing within one day of hospitalization, we do not know how long symptoms preceded seeking medical attention and testing. Corticosteroids may also have a differential effect depending on degree of inflammation,[33] but often extensive missing data and selection bias in obtaining tests such as C-reactive protein (CRP) and interleukin-6 (IL-6) make this difficult to explore in real-world data. Further, it is unclear whether the dexamethasone regimen used in RECOVERY is optimal or whether the formulation, dose and duration of corticosteroids should vary by factors such as patient age or severity of COVID-19. [2] [3] [4] 32] While most corticosteroid use in our cohort was dexamethasone, we found consistent results when including all systemic corticosteroids, and also when restricting to individuals over age 70, although other reports have found a potential for increased harm in older persons.

[31] It is also unknown whether corticosteroids have a differential effect in breakthrough COVID-19 after vaccination or different variants of SARS-CoV-2.

There are several limitations to our study. First, the study was observational. While we used detailed clinical data that included measures reflecting illness severity and administration of comedications in a large population well balanced by propensity for treatment, residual confounding for severity of illness could have contributed to greater mortality in those exposed to dexamethasone. Some laboratory results could have occurred after dexamethasone exposure, as both were ascertained within 48 hours. However, the impact of dexamethasone on acute laboratory results is likely limited and this approach allowed an equal time window to detect worst results in patients exposed and unexposed to dexamethasone. Although respiratory support algorithms were manually reviewed and validated, some misclassification may have occurred; but substantial separation in Kaplan-Meier curves showing increasing mortality with greater respiratory support, provides face validity. We also cannot rule out alternative indications for dexamethasone beyond COVID-19 in patients not on oxygen or on NC. However, we excluded those on corticosteroids prior to admission and patients on vasopressors within the initial 48 hours. Further, we did not calculate dose and only assessed days of inpatient dexamethasone exposure. However, most patients had length of inpatient dexamethasone treatment equal to their hospital length of stay, and very few received only one dose of dexamethasone (<4%). Finally, our cohort consisted predominantly of male Veterans, but had excellent racial and geographic variability.

In summary, we found no evidence of mortality benefit at 90-days associated with early initiation of dexamethasone in patients hospitalized with COVID-19 among those on no oxygen or NC within the first 48 hours of admission, and instead found evidence of potential harm.

These findings come from a large population with detailed clinical data providing real-world evidence that was consistent using different analytic approaches to control for confounding and 

We conducted an observational cohort study using VA electronic health record (EHR) data. We patients who were then stratified by category of respiratory support ( Figure 1 ). More than one exclusion criteria could apply; the most common reason was length of stay less than 48-hours (n=3,742; 104 deaths) as these patients had insufficient time to receive dexamethasone. This was followed by any systemic corticosteroid exposure prior to index date (n=2,046), defined as any corticosteroids within 14 days, or receipt of corticosteroids for ≥14 days in the preceding 45 days. We excluded patients who were transferred from another acute care hospital (VA or non-VA) and who were likely incidentally-detected through screening prior to or at admission; this included patients who were not admitted to an acute medical care service or had no International Classification of Diseases, 10 th Revision (ICD-10) codes for COVID-19.

In modeling mortality analyses restricted to patients who were not on oxygen or were on lowflow nasal cannula (NC) only, we excluded an additional 454 total patients; more than one exclusion criteria could also apply. Within each phase, we restricted to facilities with at least 10 cases of COVID-19 and with at least one dexamethasone prescription (n=221), and where not Results: paragraphs 1-2 Table 1 (b) Indicate number of participants with missing data for each variable of interest Figure 2 , Figure 3 Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Results: paragraph 2

Results: paragraphs 4, 5 

Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Metadata *Give information separately for exposed and unexposed groups

Dexamethasone in Hospitalized Patients with Covid-19

Effect of Hydrocortisone on 21-Day Mortality or

Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial

Rapid Evidence Appraisal for COVID-19 Therapies Working Group

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis

Use of Hydroxychloroquine, Remdesivir, and

Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study

Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome

Comparison of Associations between Glucocorticoids Treatment and Mortality in COVID-19 Patients and SARS Patients: A Systematic Review and Meta-Analysis

Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease

Double-blind, Phase IIb, Placebo-controlled Trial

Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study

Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19

Systemic corticosteroids for the treatment of COVID-19

Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study

Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study

A comparison of the Charlson comorbidity index derived from medical record data and administrative billing data